Capricor Therapeutics Inc (CAPR)
6.20
+0.56
(+9.93%)
USD |
NASDAQ |
May 17, 16:00
6.22
+0.02
(+0.32%)
After-Hours: 20:00
Capricor Therapeutics Cash from Financing (Quarterly): 2.290M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 2.290M |
| December 31, 2023 | 23.17M |
| September 30, 2023 | 0.2211M |
| June 30, 2023 | 2.188M |
| March 31, 2023 | 0.0039M |
| December 31, 2022 | 2.950M |
| September 30, 2022 | 1.882M |
| June 30, 2022 | 0.015M |
| March 31, 2022 | 0.0275M |
| December 31, 2021 | 0.0424M |
| September 30, 2021 | 6.567M |
| June 30, 2021 | 1.035M |
| March 31, 2021 | 12.58M |
| December 31, 2020 | 1.496M |
| September 30, 2020 | 2.177M |
| June 30, 2020 | 25.16M |
| March 31, 2020 | 4.550M |
| December 31, 2019 | 4.611M |
| September 30, 2019 | 2.588M |
| June 30, 2019 | 0.5457M |
| March 31, 2019 | 1.433M |
| December 31, 2018 | 0.512M |
| September 30, 2018 | 1.053M |
| June 30, 2018 | 2.775M |
| March 31, 2018 | 2.513M |
| Date | Value |
|---|---|
| December 31, 2017 | 3.026M |
| September 30, 2017 | 4.622M |
| June 30, 2017 | 3.932M |
| March 31, 2017 | 0.00 |
| December 31, 2016 | 0.00 |
| September 30, 2016 | 11.70M |
| June 30, 2016 | 2.00M |
| March 31, 2016 | 4.931M |
| December 31, 2015 | 0.00 |
| September 30, 2015 | 0.0101M |
| June 30, 2015 | 0.0004M |
| March 31, 2015 | 16.48M |
| December 31, 2014 | 0.0002M |
| September 30, 2014 | 0.5163M |
| June 30, 2014 | 4.688M |
| March 31, 2014 | 0.0009M |
| December 31, 2013 | -0.0018M |
| September 30, 2013 | 3.068M |
| June 30, 2013 | 0.0018M |
| March 31, 2013 | 0.8573M |
| December 31, 2012 | 3.806M |
| September 30, 2012 | 0.00 |
| June 30, 2012 | 1.194M |
| March 31, 2012 | 0.00 |
| December 31, 2011 | 0.0025M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
0.0039M
Minimum
Mar 2023
25.16M
Maximum
Jun 2020
4.705M
Average
2.183M
Median
Cash from Financing (Quarterly) Benchmarks
| Sarepta Therapeutics Inc | 22.14M |
| PTC Therapeutics Inc | 0.54M |
| Solid Biosciences Inc | 107.24M |
| Inovio Pharmaceuticals Inc | -11.36M |
| Stereotaxis Inc | 0.03M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -1.268M |
| Cash from Investing (Quarterly) | -9.502M |
| Free Cash Flow | -33.33M |
| Free Cash Flow Per Share (Quarterly) | -0.0616 |
| Free Cash Flow to Equity (Quarterly) | -1.933M |
| Free Cash Flow Yield | -19.00% |